Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
11 October 2016Website:
http://www.enterothera.comNext earnings report:
14 May 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Thu, 21 Nov 2024 00:45:14 GMTDividend
Analysts recommendations
Institutional Ownership
ENTO Latest News
NEW YORK, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Entero Therapeutics, Inc. (NASDAQ: ENTO ), relating to the proposed merger with Journey Therapeutics, Inc. Under the terms of the agreement, the shareholders of Journey will acquire 99% of the equity of Entero.
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Entero Therapeutics, Inc. (NASDAQ: ENTO) and Journey Therapeutics, Inc. is fair to Entero shareholders. Upon closing of the proposed transaction, Journey shareholders will acquire 99% of the equity of Entero. Halper Sadeh encourages Entero shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh.
New VCIEL scale provides a more sensitive and quantitative metric of small intestinal health for monitoring Celiac Disease severity and treatment efficacy
What type of business is Entero Therapeutics?
Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis. It is also involved in the development of adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, currently under Phase 2 studies for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis; and niclosamide, an oral small molecule with anti-inflammatory inhibitor therapy, currently under Phase 2 studies for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis, as well as immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients. The company was formerly known as First Wave BioPharma, Inc. and changed its name to Entero Therapeutics, Inc. in May 2024. Entero Therapeutics, Inc. was incorporated in 2014 and is based in Boca Raton, Florida.
What sector is Entero Therapeutics in?
Entero Therapeutics is in the Healthcare sector
What industry is Entero Therapeutics in?
Entero Therapeutics is in the Biotechnology industry
What country is Entero Therapeutics from?
Entero Therapeutics is headquartered in United States
When did Entero Therapeutics go public?
Entero Therapeutics initial public offering (IPO) was on 11 October 2016
What is Entero Therapeutics website?
https://www.enterothera.com
Is Entero Therapeutics in the S&P 500?
No, Entero Therapeutics is not included in the S&P 500 index
Is Entero Therapeutics in the NASDAQ 100?
No, Entero Therapeutics is not included in the NASDAQ 100 index
Is Entero Therapeutics in the Dow Jones?
No, Entero Therapeutics is not included in the Dow Jones index
When was Entero Therapeutics the previous earnings report?
No data
When does Entero Therapeutics earnings report?
The next expected earnings date for Entero Therapeutics is 14 May 2025